Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0CT7M
|
|||
Former ID |
DIB009653
|
|||
Drug Name |
A-6
|
|||
Synonyms |
Angstrom-6; CD44 binding peptide (cancer), Angstrom
Click to Show/Hide
|
|||
Indication | Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Phase 2 | [1] | |
Company |
Angstrom pharmaceuticals
|
|||
Structure |
Download2D MOL |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Extracellular matrix receptor III (CD44) | Target Info | Modulator | [2], [3] |
KEGG Pathway | ECM-receptor interaction | |||
Hematopoietic cell lineage | ||||
Shigellosis | ||||
Epstein-Barr virus infection | ||||
Proteoglycans in cancer | ||||
MicroRNAs in cancer | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
RANKL Signaling Pathway | ||||
TNFalpha Signaling Pathway | ||||
Panther Pathway | Alzheimer disease-presenilin pathway | |||
Pathway Interaction Database | Osteopontin-mediated events | |||
a4b7 Integrin signaling | ||||
Reactome | Degradation of the extracellular matrix | |||
Cell surface interactions at the vascular wall | ||||
Integrin cell surface interactions | ||||
Hyaluronan uptake and degradation | ||||
Interferon gamma signaling | ||||
WikiPathways | Senescence and Autophagy in Cancer | |||
Wnt Signaling Pathway and Pluripotency | ||||
Glycosaminoglycan metabolism | ||||
Extracellular matrix organization |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011940) | |||
REF 2 | Modulation of CD44 Activity by A6-Peptide.Front Immunol.2015 Mar 30;6:135. | |||
REF 3 | A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.Mol Cancer Ther.2011 Nov;10(11):2072-82. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.